Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1481

Shown on this page

Current sort

Live official records

Conditions: Epilepsy
Interventions: EEG, Eye Tracking, Behavioral task, fMRI; Device · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 13 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 5 more

Conditions: Peripartum Cardiomyopathy, Postpartum
Interventions: Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo; Drug
Lead sponsor: Dennis M. McNamara, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 64
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more

Conditions: Hip Pain Chronic, Hip Pain, Physical Medicine and Rehabilitation
Interventions: HIPS-1, HIPS-2; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Giant Cell Arteritis (GCA)
Interventions: Tocilizumab, Discontinue Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Breast Neoplasms
Interventions: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions: Riliprubart, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Homewood, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Brain Tumor
Interventions: Proton Beam; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions: TriPRIL CAR T Cells, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Amani; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Breast Cancer
Interventions: MEN2312, Elacestrant; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 37
States / cities: Springdale, Arkansas • Duarte, California • La Jolla, California + 30 more

Conditions: Prostate Cancer
Interventions: Abemaciclib, Placebo, Abiraterone acetate, Prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 20 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

Subcortical Arousal in Perceptual Awareness

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

HIPS Feasibility Randomized Controlled Trial

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation

TriPRIL CAR T Cells in Multiple Myeloma

Feasibility and Acceptability of Amani

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

About this Massachusetts General Hospital institution page